A detailed history of Trust CO Of Vermont transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Trust CO Of Vermont holds 300 shares of ESPR stock, worth $699. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300
Previous 300 -0.0%
Holding current value
$699
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$2.02 - $3.02 $606 - $906
300 New
300 $0
Q2 2022

Jul 20, 2022

BUY
$4.77 - $6.67 $1,430 - $2,001
300 New
300 $2,000
Q1 2022

Apr 05, 2022

SELL
$3.34 - $5.56 $1,002 - $1,667
-300 Closed
0 $0
Q4 2021

Jan 21, 2022

BUY
$4.81 - $11.92 $1,442 - $3,576
300 New
300 $2,000
Q3 2021

Oct 22, 2021

SELL
$11.34 - $21.37 $3,402 - $6,411
-300 Closed
0 $0
Q3 2017

Oct 24, 2017

BUY
$43.8 - $52.77 $13,140 - $15,831
300
300 $15,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $155M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Trust CO Of Vermont Portfolio

Follow Trust CO Of Vermont and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trust CO Of Vermont, based on Form 13F filings with the SEC.

News

Stay updated on Trust CO Of Vermont with notifications on news.